United Therapeutics Corporation (UTHR) Performs First UThymoKidney Trial Transplant
United Therapeutics (UTHR) performed the first xenotransplant in its EXTEND study of UThymoKidney for end-stage renal disease patients. The trial aims to assess safety and efficacy, with no data reported yet. The next milestone is data review after 12 weeks for the first six participants.

